Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
suxinding sulfate
- Development stage
- Unknown
- Lead developer
- Zhejiang Zhongbao Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Suxinding sulfate (硫酸舒欣啶) is a small molecule Class III antiarrhythmic agent developed by Hebei Zhongbao Pharmaceutical. Administered via injection, it is specifically designed for the rapid conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. As a Class III antiarrhythmic, its primary mechanism involves the blockade of cardiac potassium channels, which leads to a prolongation of the action potential duration and the effective refractory period in myocardial tissues. This action helps stabilize cardiac rhythm without significantly impacting the conduction velocity of the heart. The drug is currently in Phase 2 clinical development in China.
- Other names
- Suxinding Sulfate Injection硫酸舒欣啶注射液Suxinding
Beyond the preview
Go deeper on suxinding sulfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on suxinding sulfate.